| 词条 | Tezepelumab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = u | target = TSLP | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration = Subcutaneous injection | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1572943-04-4 | ATC_prefix = none | ATC_suffix = | PubChem = | ChemSpiderID = none | DrugBank = | C = 6400 | H = 9844 | N = 1732 | O = 1992 | S = 52 | molecular_weight = 144.6 kDa | UNII = RJ1IW3B4QX | synonyms = MEDI9929, AMG 157 }}Tezepelumab (INN) (MEDI9929, AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis.[1][2] It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[3] This drug is being developed in collaboration by MedImmune, LLC and Amgen. It is in Phase III trials {{as of|2018|10|lc=on}}. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Tezepelumab, American Medical Association. {{monoclonals for immune system}}{{monoclonal-antibody-stub}}2. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 | journal = WHO Drug Information | volume = 29 | issue = 2 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf | format=PDF}} 3. ^[https://www.astrazeneca.com/media-centre/press-releases/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018.html#! Tezepelumab granted Breakthrough Therapy Designation by US FDA - AstraZeneca Press Release] 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。